Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT05911295
- Locations
- 🇺🇸
Foothill Cardioology, Arcadia, California, United States
🇺🇸Beverly Hills Multi-Specialties Practice, Beverly Hills, California, United States
🇦🇷Hospital Municipal de Morón. O. B. Lavignolle, Morón, Argentina
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
- Conditions
- Urothelial Carcinoma
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT05902494
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸Stanford Cancer Institute - School of Medicine, Palo Alto, California, United States
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- Conditions
- Non-small Cell Lung CancerPancreatic NeoplasmsMesotheliomaCutaneous MelanomaColorectal Neoplasms
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT05571839
- Locations
- 🇺🇸
Presbyterian/St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸BWH, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT05253651
- Locations
- 🇺🇸
Pacific Cancer Medical Center Inc., Anaheim, California, United States
🇺🇸Palo Verde Hematology Oncology, Glendale, Arizona, United States
🇺🇸Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States
A Safety Study of Brentuximab Vedotin in Participants With HIV
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT05244473
- Locations
- 🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
A Study of SGN-ALPV in Advanced Solid Tumors
- Conditions
- Ovarian NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungStomach NeoplasmsGastroesophageal Junction CarcinomaUterine Cervical NeoplasmsTesticular Neoplasms
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT05229900
- Locations
- 🇺🇸
Women's Cancer Care, Fresno, California, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇨🇦University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Conditions
- Carcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of the Head and NeckMelanomaEsophageal Squamous Cell CarcinomaOvarian NeoplasmsTriple Negative Breast NeoplasmsGastric Cancer
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 315
- Registration Number
- NCT05208762
- Locations
- 🇩🇪
Apotheke-Zytostatika Studien Charite- Universitatsmedizin Berlin Campus Virchow Klinkum, Berlin, Germany
🇨🇳Shanghai East Hospital, Shanghai, Shanghai, China
🇮🇹UOC Oncologia - IRCCS Azienda Ospedaliero Universitaria Bologna, Bologna, Italy
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
- Conditions
- Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube NeoplasmsTriple Negative Breast NeoplasmsHER2 Negative Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungCholangiocarcinomaGallbladder Carcinoma
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 236
- Registration Number
- NCT05194072
- Locations
- 🇺🇸
UCHealth Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇺🇸University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 650
- Registration Number
- NCT05132582
- Locations
- 🇨🇱
James Lind Centro De Investigacion Del Cancer, Temuco, Chile
🇨🇳The Second Hospital of Anhui Medical University, Hefei City, Anhui, China
🇩🇪Universitatsklinikum Wurzburg Apotheke, Wurzburg, Germany
A Study of SEA-CD40 Given With Other Drugs in Cancers
- Conditions
- Carcinoma, Non-Small- Cell LungMelanoma
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT04993677
- Locations
- 🇺🇸
Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Allina Health Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States